Fujirebio, a subsidiary of H.U. Group Holdings Inc., has announced the receipt of Class II Medical Device Licenses from Health Canada for its Lumipulse G NfL Blood and Lumipulse G pTau 217 Plasma assays. These assays can be utilized on the fully automated LUMIPULSE G immunoassay platform, allowing for advanced testing in neurological conditions.
The Lumipulse G NfL Blood assay measures neurofilament light chain (NfL) levels, which are significant biomarkers for neurological disorders such as multiple sclerosis, amyotrophic lateral sclerosis, and Alzheimer’s disease. Similarly, the Lumipulse G pTau 217 Plasma assay is designed to quantify phosphorylated tau protein, another critical marker in diagnosing Alzheimer's disease.
This approval is an important development as it enhances the accessibility of diagnostic tools for healthcare professionals dealing with neurodegenerative diseases in Canada. The launch of these tests is expected to improve patient outcomes by enabling earlier diagnosis and better management of neurological conditions. Fujirebio's expansion into Canada aligns with the increasing demand for reliable blood-based diagnostic assays in the medical field, particularly in neurology.
Analyzed Canadian Outlets (3)
2 headlines · wire copies grouped